Cited by 379Hepatitis C virus researchDrug-Induced Hepatotoxicity and ProtectionLiver physiology and pathology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients: Mitoquinone and liver damage

Gane, Edward J., Weilert, Frank, Orr, David W., Keogh, Geraldine F., Gibson, Michael, Lockhart, Michelle M., Frampton, Christopher M., Taylor, Kenneth M., Smith, Robin A. J., Murphy, Michael P.·2010·Liver International

DOI 10.1111/j.1478-3231.2010.02250.x

Open this paper in CoChat — free account

Abstract

BACKGROUND: Increased oxidative stress and subsequent mitochondrial damage are important pathways for liver damage in chronic hepatitis C virus (HCV) infection; consequently, therapies that decrease mitochondrial oxidative damage may improve outcome. The mitochondria-targeted anti-oxidant mitoquinone combines a potent anti-oxidant with a lipophilic cation that causes it to accumulate several-hundred fold within mitochondria in vivo. AIMS: In this phase II study, we investigated the effect of oral mitoquinone on serum aminotransferases and HCV RNA levels in HCV-infected patients. METHODS: Thirty HCV patients who were either non-responders or unsuitable candidates for standard-of-care (pegylated interferon plus ribavirin) were randomized to receive mitoquinone (40 or 80 mg) or placebo once daily for 28 days, and serum aminotransferases and HCV RNA levels were measured. RESULTS: Both treatment groups showed significant decreases in absolute and percentage changes in serum alanine transaminase (ALT) from baseline to treatment day 28 (P<0.05). There was also a significant difference between incremental area under the curve for ALT between baseline and day 28 for the 40 mg treatment group against placebo (P<0.05). The differences in plasma ALT activity from baseline to day 28 in both mitoquinone groups compared with placebo did not reach significance (P>0.05). There was no change in HCV load on mitoquinone treatment. CONCLUSIONS: Administration of the mitochondria-targeted anti-oxidant mitoquinone significantly decreased plasma ALT and aspartate aminotransferase in patients with chronic HCV infection, and this suggests that mitoquinone may decrease necroinflammation in the liver in these patients. As mitochondrial oxidative damage contributes to many other chronic liver diseases, such as steatohepatitis, further studies using mitochondria-targeted anti-oxidants in HCV and other liver diseases are warranted.

Integrity signals

Registry

Crossref · 10.1111/j.1478-3231.2010.02250.x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Self-citation
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,457
The global burden of hepatitis C
Lavanchy, D. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01934.x · Cited by 1,353
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J. W. F., Heathcote, E. J., Lai, M., Gane, E. J., O’Grady, J., Reichen, J., Moisés Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,218
Self-citation
Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173
Self-citation
Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009093200 · Cited by 1,091
Self-citation
Global surveillance and control of hepatitis C
(1999) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.1999.6120139.x · Cited by 903
Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C
Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00008 · Cited by 867
Non‐alcoholic fatty liver disease
Angulo, P., & Lindor, K. D. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.17.s1.10.x · Cited by 838
Delivery of bioactive molecules to mitochondria in vivo
Smith, R. A. J., Porteous, C. M., Gane, A. M., & Murphy, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931245100 · Cited by 725
Self-citation

Show all 33 references

Research works printed but not linked: 5

Reddy, 2009, Ribavirin, current role in the optimal clinical management of chronic hepatitis C, 50, 402
Chandran, 2009, Doxorubicin inactivates myocardial cytochrome c oxidase in rats, cardioprotection by Mito-Q, 96, 1388
Murphy, 2000, Drug delivery to mitochondria, the key to mitochondrial medicine, 41, 235
Snow, 2008, Phase II study of the mitochondrial antioxidant mitoquinone for Parkinson's disease, Neurology, 70, A483
Begriche, 2006, Mitochondrial dysfunction in NASH, causes, consequences and possible means to prevent it, 6, 1

Sorted by citations

Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release
Zorov, D. B., Juhaszova, M., & Sollott, S. J. (2014) · Physiological Reviews · doi:10.1152/physrev.00026.2013 · Cited by 5,383
Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease
Lood, C., Blanco, L. P., Purmalek, M. M., Carmona-Rivera, C., De Ravin, S. S., Smith, C. K., Malech, H. L., Ledbetter, J. A., Elkon, K. B., & Kaplan, M. J. (2016) · Nature Medicine · doi:10.1038/nm.4027 · Cited by 1,570
Mechanisms of hepatic fibrogenesis
Lee, U. E., & Friedman, S. L. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.005 · Cited by 923
Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances
Xu, X., Pang, Y., & Fan, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02253-4 · Cited by 1,016
Mitochondria as a therapeutic target for common pathologies
Murphy, M. P., & Hartley, R. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.174 · Cited by 846
Self-citation
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 785
Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy
Yang, Y., Karakhanova, S., Hartwig, W., D’Haese, J. G., Philippov, P. P., Werner, J., & Bazhin, A. V. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25349 · Cited by 686
Mitochondria in health, disease, and aging
Harrington, J. S., Ryter, S. W., Plataki, M. E., Price, D. R., & Choi, A. M. K. (2023) · Physiological Reviews · doi:10.1152/physrev.00058.2021 · Cited by 641
The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1
Xiao, L., Xu, X., Zhang, F., Wang, M., Xu, Y., Tang, D., Wang, J., Qin, Y., Liu, Y., Tang, C., et al. (2016) · Redox Biology · doi:10.1016/j.redox.2016.12.022 · Cited by 568
Animal and human studies with the mitochondria‐targeted antioxidant MitoQ
Smith, R. A. J., & Murphy, M. P. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05627.x · Cited by 560
Self-citation
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Oxidative stress, anti‐oxidant therapies and chronic kidney disease
Small, D. M., Coombes, J. S., Bennett, N. J., Johnson, D. W., & Gobe, G. C. (2012) · Nephrology · doi:10.1111/j.1440-1797.2012.01572.x · Cited by 529
Mitochondria and Endothelial Function
Kluge, M. A., Fetterman, J. L., & Vita, J. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300233 · Cited by 508
Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes
Karam, B. S., Alejandro, C.-M., Koh, W.-J., Akar, J. G., & Akar, F. G. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0604-9 · Cited by 517
Mitochondrial pharmacology
Smith, R. A. J., Hartley, R. C., Cochemé, H. M., & Murphy, M. P. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.010 · Cited by 514
Self-citation
Mitochondrial oxidative stress in aging and healthspan
Dai, D., Chiao, Y. A., Marcinek, D. J., Szeto, H. H., & Rabinovitch, P. S. (2014) · Longevity & Healthspan · doi:10.1186/2046-2395-3-6 · Cited by 496
Mitochondria‐targeted antioxidants
Oyewole, A. O., & Birch‐Machin, M. A. (2015) · The FASEB Journal · doi:10.1096/fj.15-275404 · Cited by 467
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults
Rossman, M. J., Santos-Parker, J. R., Steward, C. A. C., Bispham, N. Z., Cuevas, L. M., Rosenberg, H. L., Woodward, K. A., Chonchol, M., Gioscia-Ryan, R. A., Murphy, M. P., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10787 · Cited by 456
Self-citation
Role of Mitochondrial Calcium and the Permeability Transition Pore in Regulating Cell Death
Bauer, T. M., & Murphy, E. (2020) · Circulation Research · doi:10.1161/circresaha.119.316306 · Cited by 450
Mitochondria-Targeted Small Molecule Therapeutics and Probes
Smith, R. A. J., Hartley, R. C., & Murphy, M. P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3969 · Cited by 399
Self-citation
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update
Elpek, G. Ö. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7260 · Cited by 399
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes
Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., & Kanthasamy, A. G. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.007 · Cited by 373
Mitochondria as a Cellular Hub in Infection and Inflammation
Andrieux, P., Chevillard, C., Cunha-Neto, E., & Nunes, J. P. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111338 · Cited by 346
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B
Fisicaro, P., Barili, V., Montanini, B., Acerbi, G., Ferracin, M., Guerrieri, F., Salerno, D., Boni, C., Massari, M., Cavallo, M. C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4275 · Cited by 356
Mitochondria in acute myocardial infarction and cardioprotection
Ramachandra, C. J. A., Hernández‐Reséndiz, S., Crespo-Avilan, G. E., Lin, Y., & Hausenloy, D. J. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102884 · Cited by 348
Cardiac Aging: From Molecular Mechanisms to Significance in Human Health and Disease
Dai, D.-F., Chen, T., Johnson, S. C., Szeto, H., & Rabinovitch, P. S. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4179 · Cited by 334
Mitochondria as a Therapeutic Target in Heart Failure
Bayeva, M., Gheorghiade, M., & Ardehali, H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1021 · Cited by 340
Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives
Battogtokh, G., Choi, Y. S., Kang, D. S., Park, S. J., Shim, M. S., Huh, K. M., Cho, Y., Lee, J. Y., Lee, H. S., & Kang, H. C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.006 · Cited by 318
Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction
Kumar, A. A., Kelly, D. P., & Chirinos, J. A. (2019) · Circulation · doi:10.1161/circulationaha.118.036259 · Cited by 297
Mitochondrial Quality Control as a Therapeutic Target
Suliman, H. B., & Piantadosi, C. A. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 266
Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice
Gioscia‐Ryan, R. A., LaRocca, T. J., Sindler, A. L., Zigler, M. C., Murphy, M. P., & Seals, D. R. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2013.268680 · Cited by 263
Self-citation
Structural Features of Small Molecule Antioxidants and Strategic Modifications to Improve Potential Bioactivity
Charlton, N. C., Mastyugin, M., Török, B., & Török, M. (2023) · Molecules · doi:10.3390/molecules28031057 · Cited by 292
Targeting Oxidative Stress for the Treatment of Liver Fibrosis
Luangmonkong, T., Suriguga, S., Mutsaers, H. A. M., Groothuis, G. M. M., Olinga, P., & Boersema, M. (2018) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2018_10 · Cited by 252
Antioxidants as therapeutic agents for liver disease
Singal, A. K., Jampana, S. C., & Weinman, S. A. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02604.x · Cited by 236
Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically?
Macdonald, R., Barnes, K., Hastings, C., & Mortiboys, H. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170501 · Cited by 223
Mechanisms of Endothelial Dysfunction in Pre-eclampsia and Gestational Diabetes Mellitus: Windows Into Future Cardiometabolic Health?
McElwain, C. J., Tuboly, E., McCarthy, F. P., & McCarthy, C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00655 · Cited by 236
The mitochondria‐targeted anti‐oxidant MitoQ protects against intervertebral disc degeneration by ameliorating mitochondrial dysfunction and redox imbalance
Kang, L., Liu, S., Li, J., Tian, Y., Xue, Y., & Liu, X. (2020) · Cell Proliferation · doi:10.1111/cpr.12779 · Cited by 218
Mitochondria-Targeted Drugs
Zinovkin, R. A., & Zamyatnin, A. A. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666181127151059 · Cited by 209
Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention
Cunha‐Oliveira, T., Montezinho, L., Mendes, C., Firuzi, O., Saso, L., Oliveira, P. J., & Silva, F. S. G. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5021694 · Cited by 220
Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines
Dashdorj, A., Jyothi, K. R., Lim, S., Jo, A., Nguyen, M. N., Ha, J., Yoon, K., Kim, H. J., Park, J., Murphy, M. P., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-178 · Cited by 206
Self-citation
Mitochondria-Targeted Antioxidants: A Step towards Disease Treatment
Jiang, Q., Yin, J., Chen, J., Ma, X., Wu, M., Liu, G., Kang, Y., Tan, B., & Yin, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8837893 · Cited by 212
Prevention of diabetic nephropathy in Ins2+/−AkitaJ mice by the mitochondria-targeted therapy MitoQ
Chacko, B. K., Reily, C., Srivastava, A., Johnson, M. S., Ye, Y., Ulasova, E., Agarwal, A., Zinn, K. R., Murphy, M. P., Kalyanaraman, B., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100308 · Cited by 204
Self-citation
Protection against renal ischemia–reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ
Dare, A. J., Bolton, E. A., Pettigrew, G. J., Bradley, J. A., Saeb-Parsy, K., & Murphy, M. P. (2015) · Redox Biology · doi:10.1016/j.redox.2015.04.008 · Cited by 202
Self-citation
Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
Zheng, Y., Wang, S., Wu, J., & Wang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04367-1 · Cited by 197
Organelle-level precision with next-generation targeting technologies
Saminathan, A., Zajac, M. A., Anees, P., & Krishnan, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00396-8 · Cited by 194
NOD-like receptor signaling in inflammation-associated cancers: From functions to targeted therapies
Liu, P., Lu, Z., Liu, L., Li, R., Liang, Z., Shen, M., Han, X., Ren, D., Ji, M., Yuan, S., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152925 · Cited by 174
Cardiopulmonary Bypass and Oxidative Stress
Zakkar, M., Guida, G. A., Suleiman, M. S., & Angelini, G. D. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/189863 · Cited by 171
Anxiety and Brain Mitochondria: A Bidirectional Crosstalk
Filiou, M. D., & Sandi, C. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.07.002 · Cited by 170
Mitochondria and Inflammatory Bowel Diseases: Toward a Stratified Therapeutic Intervention
Ho, G., & Theiss, A. L. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-060821-083306 · Cited by 166
A Selective Mitochondrial-Targeted Chlorambucil with Remarkable Cytotoxicity in Breast and Pancreatic Cancers
Millard, M., Gallagher, J. D., Olenyuk, B. Z., & Neamati, N. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012438 · Cited by 160
Understanding and preventing mitochondrial oxidative damage
Murphy, M. P. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160108 · Cited by 165
Self-citation
Oxidative stress and hepatitis C virus
Paracha, U. Z., Fatima, K., Alqahtani, M. H., Chaudhary, A., Abuzenadah, A. M., Damanhouri, G. A., & Qadri, I. (2013) · Virology Journal · doi:10.1186/1743-422x-10-251 · Cited by 161
Oxidative Stress and Ischemia/Reperfusion Injury in Kidney Transplantation: Focus on Ferroptosis, Mitophagy and New Antioxidants
Granata, S., Votrico, V., Spadaccino, F., Catalano, V., Netti, G. S., Ranieri, E., Stallone, G., & Zaza, G. (2022) · Antioxidants · doi:10.3390/antiox11040769 · Cited by 158
The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease
Solesio, M. E., Prime, T. A., Logan, A., Murphy, M. P., Jiménez, M. D. M. A., Jordán, J., & Galindo, M. F. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.07.009 · Cited by 150
Self-citation
Molecular Vehicles for Mitochondrial Chemical Biology and Drug Delivery
Jean, S. R., Tulumello, D. V., Wisnovsky, S., Lei, E. K., Pereira, M. P., & Kelley, S. O. (2014) · ACS Chemical Biology · doi:10.1021/cb400821p · Cited by 150
Mitoquinone ameliorates pressure overload-induced cardiac fibrosis and left ventricular dysfunction in mice
Goh, K. Y., He, L., Song, J., Jinno, M., Rogers, A. J., Sethu, P., Halade, G. V., Rajasekaran, N. S., Liu, X., Prabhu, S. D., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101100 · Cited by 144
Reduction in mitochondrial iron alleviates cardiac damage during injury
Chang, H., Wu, R., Shang, M., Sato, T., Chen, C., Shapiro, J. S., Liu, T., Thakur, A., Sawicki, K. T., Prasad, S. V. N., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505748 · Cited by 137
Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing
Gruber, J., Fong, S., Chen, C.-B., Yoong, S. L., Pastorin, G., Schaffer, S., Cheah, I. K.-M., & Halliwell, B. B. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.09.005 · Cited by 143
Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism
Mantle, D., & Dybring, A. (2020) · Antioxidants · doi:10.3390/antiox9050386 · Cited by 149
Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia–reperfusion: Therapeutic potential of mitochondrially targeted antioxidants
Mukhopadhyay, P., Horváth, B., Zsengellér, Z. K., Bátkai, S., Cao, Z., Kechrid, M., Holovac, E., Erdélyi, K., Tanchian, G., Liaudet, L., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.036 · Cited by 132
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 142
Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: A possible approach to SARS‐CoV‐2 ‘long‐haulers’?
Wood, E., Hall, K., & Tate, W. P. (2020) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2020.11.002 · Cited by 132
Mitochondria‐Targeted Antioxidants: Future Perspectives in Kidney Ischemia Reperfusion Injury
Kezić, A., Spasojević, I., Ležaić, V., & Bajčetić, M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2950503 · Cited by 135
Mitochondria-targeted therapeutics, MitoQ and BGP-15, reverse aging-associated meiotic spindle defects in mouse and human oocytes
Al-Zubaidi, U., Adhikari, D., Çınar, Ö., Zhang, Q.-H., Yuen, W. S., Murphy, M. P., Rombauts, L. J. F., Robker, R. L., & Carroll, J. (2020) · Human Reproduction · doi:10.1093/humrep/deaa300 · Cited by 124
Self-citation
Riding the tiger – physiological and pathological effects of superoxide and hydrogen peroxide generated in the mitochondrial matrix
Brand, M. D. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1828258 · Cited by 123
Mitochondrial dysfunction and tissue injury by alcohol, high fat, nonalcoholic substances and pathological conditions through post-translational protein modifications
Song, B.-J., Akbar, M., Abdelmegeed, M. A., Byun, K., Lee, B., Yoon, S. K., & Hardwick, J. P. (2014) · Redox Biology · doi:10.1016/j.redox.2014.10.004 · Cited by 123
“Thus, protein nitration serves as one of the critical causal factors in APAP-induced acute liver damage usually observed at later time points.”
Background
Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis
Chacko, B. K., Srivastava, A., Johnson, M. S., Benavides, G. A., Chang, M. J., Ye, Y., Jhala, N., Murphy, M. P., Kalyanaraman, B., & Darley-Usmar, V. M. (2011) · Hepatology · doi:10.1002/hep.24377 · Cited by 122
Self-citation
Mitochondria: a new therapeutic target in chronic kidney disease
Granata, S., Gassa, A. D., Tomei, P., Lupo, A., & Zaza, G. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0044-z · Cited by 122
Rapid uptake of lipophilic triphenylphosphonium cations by mitochondria in vivo following intravenous injection: Implications for mitochondria-specific therapies and probes
Porteous, C. M., Logan, A., Evans, C., Ledgerwood, E. C., Menon, D. K., Aigbirhio, F., Smith, R. A. J., & Murphy, M. P. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.06.001 · Cited by 121
Self-citation
Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin
Yoong, S. L., Wong, B. S., Zhou, Q., Chin, C. F., Li, J., Venkatesan, T., Ho, H. K., Yu, V. C. K., Ang, W. H., & Pastorin, G. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.036 · Cited by 123
Evolving Concepts of Oxidative Stress and Reactive Oxygen Species in Cardiovascular Disease
Chen, K., & Keaney, J. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0266-8 · Cited by 122
Mitochondrial calcium and reactive oxygen species in cardiovascular disease
Murphy, E., & Liu, J. C. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac134 · Cited by 123
The mitochondria-targeted anti-oxidant MitoQ decreases ischemia-reperfusion injury in a murine syngeneic heart transplant model
Dare, A. J., Logan, A., Prime, T. A., Rogatti, S., Goddard, M., Bolton, E. M., Bradley, J. A., Pettigrew, G. J., Murphy, M. P., & Saeb-Parsy, K. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.05.007 · Cited by 119
Self-citation
Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy
Cheng, X., Feng, D., Lv, J., Cui, X., Wang, Y., Wang, Q., & Zhang, L. (2023) · Cancers · doi:10.3390/cancers15030666 · Cited by 118
Role of Metabolic Reprogramming in Pulmonary Innate Immunity and Its Impact on Lung Diseases
Michaeloudes, C., Bhavsar, P. K., Mumby, S. E., Xu, B., Hui, C., Chung, K. F., & Adcock, I. M. (2019) · Journal of Innate Immunity · doi:10.1159/000504344 · Cited by 115
Mitochondria-Targeted Antioxidants for Treatment of Hearing Loss: A Systematic Review
Fujimoto, C., & Yamasoba, T. (2019) · Antioxidants · doi:10.3390/antiox8040109 · Cited by 109
Potential therapy strategy: targeting mitochondrial dysfunction in sepsis
Zhang, H., Feng, Y., & Yao, Y.-M. (2018) · Military Medical Research · doi:10.1186/s40779-018-0187-0 · Cited by 113
Infection with the dengue RNA virus activates TLR9 signaling in human dendritic cells
Lai, J., Wang, M., Huang, C., Wu, C., Hung, L., Yang, C., Ke, P., Luo, S., Liu, S., & Ho, L. (2018) · EMBO Reports · doi:10.15252/embr.201846182 · Cited by 111
Role of Drp1, a Key Mitochondrial Fission Protein, in Neuropathic Pain
Ferrari, L. F., Chum, A., Bogen, O., Reichling, D. B., & Levine, J. D. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2223-11.2011 · Cited by 107
Mitochondria-targeted Antioxidants Protect Pancreatic β-cells against Oxidative Stress and Improve Insulin Secretion in Glucotoxicity and Glucolipotoxicity
Lim, S., Rashid, M. A., Jang, M., Kim, Y., Won, H., Lee, J., Woo, J., Kim, Y. S., Murphy, M. P., Ali, L., et al. (2011) · Cellular Physiology and Biochemistry · doi:10.1159/000335802 · Cited by 107
Self-citation
New antiviral therapies for chronic hepatitis C
Kanda, T., Imazeki, F., & Yokosuka, O. (2010) · Hepatology International · doi:10.1007/s12072-010-9193-3 · Cited by 105
Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy
Dong, L., Jameson, V. J. A., Tilly, D., Procházka, L., Rohlena, J., Vališ, K., Truksa, J., Zobalová, R., Mahdavian, E., Kľučková, K., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.02.032 · Cited by 106
Self-citation
Mitochondrion‐Permeable Antioxidants to Treat ROS‐Burst‐Mediated Acute Diseases
Zhang, Z., Xu, X., Liu, T., & Yuan, S. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/6859523 · Cited by 108
Specific inhibition of mitochondrial oxidative stress suppresses inflammation and improves cardiac function in a rat pneumonia-related sepsis model
Zang, Q. S., Sadek, H. A., Maass, D. L., Martinez, B., Ma, L., Kilgore, J. A., Williams, N. S., Frantz, D. E., Wigginton, J. G., Nwariaku, F. E., et al. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00203.2011 · Cited by 104
Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis
Warne, J., Pryce, G., Hill, J. M., Shi, X., Lennerås, F., Puentes, F., Kip, M., Hilditch, L., Walker, P., Simone, M. I., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.700385 · Cited by 99
Mitochondrial Dysfunction in Cardiovascular Diseases: Potential Targets for Treatment
Yang, J., Guo, Q., Feng, X., Liu, Y., & Zhou, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.841523 · Cited by 105
Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver
Yamada, Y., Nakamura, K., Abe, J., Hyodo, M., Haga, S., Ozaki, M., & Harashima, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.037 · Cited by 99
Mitochondrial energetics and calcium coupling in the heart
Kohlhaas, M., Nickel, A. G., & Maack, C. (2017) · The Journal of Physiology · doi:10.1113/jp273609 · Cited by 102
Rapamycin‐mediated mouse lifespan extension: Late‐life dosage regimes with sex‐specific effects
Strong, R., Miller, R. A., Bogue, M., Fernandez, E., Javors, M. A., Libert, S., Marinez, P. A., Murphy, M. P., Musi, N., Nelson, J. F., et al. (2020) · Aging Cell · doi:10.1111/acel.13269 · Cited by 92
Self-citation
Placental Adaptation to Early-Onset Hypoxic Pregnancy and Mitochondria-Targeted Antioxidant Therapy in a Rodent Model
Nuzzo, A. M., Camm, E. J., Sferruzzi-Perri, A. N., Ashmore, T. J., Yung, H. W., Cindrová‐Davies, T., Spiroski, A., Sutherland, M. R., Logan, A., Austin‐Williams, S., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.07.027 · Cited by 94
Self-citation
Triphenylphosphonium (TPP)‐Based Antioxidants: A New Perspective on Antioxidant Design
Wang, J., Li, J. Q., Xiao, Y., Fu, B., & Qin, Z. (2020) · ChemMedChem · doi:10.1002/cmdc.201900695 · Cited by 103
Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand
Maini, M. K., & Pallett, L. J. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30007-4 · Cited by 98
Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension
Pak, O., Scheibe, S., Esfandiary, A., Gierhardt, M., Sydykov, A. S., Logan, A., Fysikopoulos, A., Veit, F., Hecker, M., Kroschel, F., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01024-2017 · Cited by 95
Self-citation
Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents
Huang, M., Myers, C. R., Wang, Y., & You, M. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0425 · Cited by 99
Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr mice
Fortner, K. A., Blanco, L. P., Buskiewicz, I. A., Huang, N., Gibson, P. C., Cook, D. L., Pedersen, H. L., Yuen, P. S. T., Murphy, M. P., Perl, A., et al. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000387 · Cited by 94
Self-citation
Drug Development for the Therapy of Mitochondrial Diseases
Weissig, V. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.002 · Cited by 95
Co‐enzyme Q10 and idebenone use in Friedreich's ataxia
Parkinson, M. H., Schulz, J. B., & Giunti, P. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12322 · Cited by 92
Coenzyme Q10 Analogues: Benefits and Challenges for Therapeutics
Suarez-Rivero, J. M., Pastor‐Maldonado, C. J., Povea-Cabello, S., Álvarez-Córdoba, M., Villalón-García, I., Munuera-Cabeza, M., Suárez-Carrillo, A., Talaverón-Rey, M., & Sánchez-Alcázar, J. A. (2021) · Antioxidants · doi:10.3390/antiox10020236 · Cited by 98
Interventions for age-related diseases: Shifting the paradigm
Figueira, I., Fernandes, A. M. A., Mladenović, A., Lopez-Contreras, A. J., Henriques, C. M., Selman, C., Ferreiro, E. B., Gonos, E. S., Trejo, J. L., Misra, J., et al. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.009 · Cited by 92

Authors: Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P.
Affiliations: Auckland City Hospital (NZ)
Waikato Hospital (NZ)
University of Otago (NZ)
MRC Mitochondrial Biology Unit (GB)
Corresponding author: Gane, Edward J.
ORCID: Gane, Edward J.
Weilert, Frank
Frampton, Christopher M.
Murphy, Michael P.
Venue: Liver International
Publisher: Wiley
Published: 2010-05-18
Volume: 30
Issue: 7
Pages: 1019-1026
ISSN: 0106-9543 (ISSN-L)
1478-3223
1478-3231
DOI: 10.1111/j.1478-3231.2010.02250.x
OpenAlex: W1623473717
Cited by: 379
References: 33
Citations by year: 2026: 18 · 2025: 29 · 2024: 15 · 2023: 26 · 2022: 29 · 2021: 27 · 2020: 33 · 2019: 24 · 2018: 28 · 2017: 21 · 2016: 24 · 2015: 21 · 2014: 23 · 2013: 18 · 2012: 23
FWCI: 12.81
Type: journal article
Language: en
Open access: closed
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1932 d)
Locations: Liver International (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: mitoquinone, chronic hepatitis C, mitochondria-targeted antioxidants, oxidative stress, mitochondrial damage, liver injury, alanine aminotransferase, aspartate aminotransferase, HCV RNA viral load, necroinflammation
MeSH terms: Administration, Oral, Adult, Alanine Transaminase, Antioxidants, Antiviral Agents, Aspartate Aminotransferases, Double-Blind Method, Female, Genotype, Humans, Interferons, Liver, Male, Middle Aged, Mitochondria, Liver, Organophosphorus Compounds, Ribavirin, RNA, Viral, Time Factors, Ubiquinone, Biomarkers, Hepacivirus, Treatment Outcome, Viral Load, Hepatitis C, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients: Mitoquinone and liver damage

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks